TP53 and hepatocellular carcinoma: Two HCC cell lines with TP53 mutations, PLC/PRF/5 and Hep3B35, when treated with gemcitabine and a common HCC drug sorafenib, failed to induce RRM2B (Supplementary Fig. 9b).